Prognostic factors for malignant pericardial effusion treated by pericardial drainage in solid-malignancy patients.

Prognostic factors for malignant pericardial effusion treated by pericardial drainage in solid-malignancy patients. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Prognostic factors for malignant pericardial effusion treated by pericardial drainage in solid-malignancy patients. Abstract Text:

Kan Yonemori,Hideo Kunitoh,Koji Tsuta,Tetsutaro Tamura,Yasuaki Arai,Yasuhiro Shimada,Yasuhiro Fujiwara,Yuko Sasajima,Hisao Asamura,Tomohide Tamura,Kan Yonemori,Hideo Kunitoh,Koji Tsuta,Tetsutaro Tamura,Yasuaki Arai,Yasuhiro Shimada,Yasuhiro Fujiwara,Yuko Sasajima,Hisao Asamura,Tomohide Tamura,Kan Yonemori,Hideo Kunitoh,Koji Tsuta,Tetsutaro Tamura,Yasuaki Arai,Yasuhiro Shimada,Yasuhiro Fujiwara,Yuko Sasajima,Hisao Asamura,Tomohide Tamura,

PURPOSE: Malignant pericardial effusion is a frequent complication of advanced incurable malignancies and requires treatment. The purpose of this study was to identify prognostic factors for cytology-positive malignant pericardial effusion in patients treated by pericardial drainage. METHODS: We retrospectively analyzed a series of consecutive patients diagnosed with cytologically positive malignant pericardial effusion who were treated by pericardial drainage at the National Cancer Center Hospital, Tokyo. RESULTS: A total of 88 patients with pericardial effusion were treated by pericardial drainage, 60 patients were diagnosed with cytological positive malignant pericardial effusion including 32 with non-small cell lung cancer, 13 with breast cancer, 8 with gastrointestinal cancer, and 7 with miscellaneous cancers. Subxiphoid pericardiostomy was performed in 50 of the patients and percutaneous tube pericardiostomy in the other 10 patients. Malignant pericardial effusion recurred in 14 patients, and pericardial drainage was performed again in 9 of them. The median overall survival time was 6.1 months, and the 1-year survival rate was 28%. A multivariate analysis revealed the following significant negative prognostic factors: performance status, development of malignant pericardial effusion during chemotherapy, mediastinal lymph node enlargement, and cytologic type. (P = 0.03, 0.02, 0.01, 0.001, respectively). CONCLUSION: Patients with poor prognostic factors may be better to consider as indication of palliative therapy, even if oncologic emergency had been resolved rapidly by drainage.

Prognostic factors for malignant pericardial effusion treated by pericardial drainage in solid-malignancy patients. Publishing Authors By Initials

K Yonemori,H Kunitoh,K Tsuta,T Tamura,Y Arai,Y Shimada,Y Fujiwara,Y Sasajima,H Asamura,T Tamura,K Yonemori,H Kunitoh,K Tsuta,T Tamura,Y Arai,Y Shimada,Y Fujiwara,Y Sasajima,H Asamura,T Tamura,K Yonemori,H Kunitoh,K Tsuta,T Tamura,Y Arai,Y Shimada,Y Fujiwara,Y Sasajima,H Asamura,T Tamura,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Prognostic factors for malignant pericardial effusion treated by pericardial drainage in solid-malignancy patients. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Medical oncology (Northwood, London, England)

VOLUME: 24

Page Numbers: 425-30

Journal Abbreviation: Med. Oncol.

ISSN: 1357-0560

DAY: 5

MONTH: 10

YEAR: 2007

Prognostic factors for malignant pericardial effusion treated by pericardial drainage in solid-malignancy patients. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9435512

Prognostic factors for malignant pericardial effusion treated by pericardial drainage in solid-malignancy patients. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Prognostic factors for malignant pericardial effusion treated by pericardial drainage in solid-malignancy patients. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Prognostic factors for malignant pericardial effusion treated by pericardial drainage in solid-malignancy patients.

AFFILIATION: Division of Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan. kyonemor@ncc.go.jp

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Med Oncol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Prognostic factors for malignant pericardial effusion treated by pericardial drainage in solid-malignancy patients Related Publications

• 13C-enrichment at carbons 8 and 2 of uric acid after 13C-labeled folate dose in man.
• Antibacterial polypeptide produced by Streptomyces carzinostaticus. I. Isolation and purification of active substances.
• Concurrent chemoradiotherapy for limited-disease small cell lung cancer in elderly patients aged 75 years or older.
• Disruption of the mouse protein Ser/Thr phosphatase 2Cbeta gene leads to early pre-implantation lethality.
• Easily installable behavioral monitoring system with electric field sensor.
• Effect of platinum combined with irinotecan or paclitaxel against large cell neuroendocrine carcinoma of the lung.
• Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non small cell lung cancer treated with gefitinib.
• Establishment of cell lines that exhibit pluripotency from miniature swine periodontal ligaments.
• Genes regulating the sensitivity of solid tumor cell lines to cytotoxic agents: a literature review.
• Increasing trend of spina bifida and decreasing birth weight in relation to declining body-mass index of young women in Japan.
• Individual dose adjustment of oral busulfan using a test dose in hematopoietic stem cell transplantation.
• Inhalation and incubation with procaterol increases diaphragm muscle contractility in mice.
• Involvement of insulin-like growth factor-binding protein-related protein 1 in decidualization of human endometrial stromal cells.
• Measurement of blood vessel diameter for angiography using refraction contrast imaging.
• Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors.
• Phase I study of cisplatin analogue nedaplatin, paclitaxel, and thoracic radiotherapy for unresectable stage III non-small cell lung cancer.
• Prognostic factors for malignant pericardial effusion treated by pericardial drainage in solid-malignancy patients.
• Random evolution and coherence degradation of a high-order optical soliton train in the presence of noise.
• Recovery of respiratory motion and deformation of the liver using laparoscopic freehand 3D ultrasound system.
• Serum total bilirubin as a predictive factor for severe neutropenia in lung cancer patients treated with cisplatin and irinotecan.
• Single-longitudinal-mode scan of a pulsed double-grating Ti:sapphire oscillator.
• Specification of cell fate along the proximal-distal axis in the developing chick limb bud.
• Studies on nitrite reductase from spinach leaves. I. Further purification and some properties.
• The effect of calcium ion on the biodegradation of octylphenol polyethoxylates, and the antiandrogenic activity of their biodegradates.
• Thoracoscopic surgical navigation system for cancer localization in collapsed lung based on estimation of lung deformation.
• Wearable accelerometer in clinical use.
• [Chronic constrictive pericarditis]
• [Determination of dl-alpha-tocopherol acetate and dl-alpha-tocopherol in foods by HPLC using post-column photochemical reaction]
• [Late appearance of chronic constrictive pericarditis]
• [Pericarditis in collagen vascular disease]